Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
BASF Corporation is active in the Biotechnology & Pharmaceuticals technology area and currently has 2 pending office actions. These 2 actions are assigned to 2 distinct examiners, ensuring that each pending matter is evaluated by a different person. This distribution suggests that the company's current filings are being subjected to independent reviews by 2 distinct examiners at the patent office.
The 2 pending office actions are located in 2 distinct art units. This indicates that the company's current prosecution activity is split between different technical specialties within the Biotechnology & Pharmaceuticals sector. KETCHAM, KAREN A is the busiest examiner for the portfolio, currently managing 1 pending office action. This workload accounts for a portion of the company's 2 total pending office actions.
The remaining pending action is handled by the other of the 2 distinct examiners. With 2 pending office actions distributed across 2 distinct examiners, the company's current prosecution landscape is divided. Practitioners should be prepared to navigate separate examination tracks, as KETCHAM, KAREN A and the other examiner each oversee 1 pending office action in their respective art units.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KETCHAM, KAREN A | 1 | 19.6% | +37.2% |
| JUSTICE, GINA CHIEUN YU | 1 | 55.6% | +8.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17416049 | NOVEL COSMETIC AND DERMATOLOGICAL USES OF AN EXTRACT OF CISTUS MONSPELIENSIS | JUSTICE, GINA CHIEUN YU | 28d |
| 18805874 | NEW COSMETIC USE OF POROUS SPHERES OF METAL OXIDE | KETCHAM, KAREN A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18805874 | NEW COSMETIC USE OF POROUS SPHERES OF METAL OXIDE | KETCHAM, KAREN A | — |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18805874 | NEW COSMETIC USE OF POROUS SPHERES OF METAL OXIDE | KETCHAM, KAREN A | 1614 | §103 | Non-Final OA | — | Pending | Aug 15, 2024 |
| 17416049 | NOVEL COSMETIC AND DERMATOLOGICAL USES OF AN EXTRACT OF CISTUS MONSPELIENSIS | JUSTICE, GINA CHIEUN YU | 1617 | §102§103§112 | Final Rejection | 28d | Pending | Mar 01, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBASF Corporation has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Karen A Ketcham has the most, with 1 of BASF Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
